Liraglutide and Semaglutide Market to Exceed USD 52.4 Billion by 2034

Pune, India, November 7, 2025 - The Global Liraglutide and Semaglutide Market is projected to rise from USD 18.9 billion in 2024 to nearly USD 52.4 billion by 2034, expanding at a CAGR of 10.7 % during 2025-2034, according to Exactitude Consultancy. The phenomenal adoption of GLP-1 receptor agonists for both glycemic control and chronic-weight-management therapy continues to reshape the metabolic-disease landscape.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/48108

Key Takeaways
• Market Size (2024): USD 18.9 Billion
• Forecast (2034): USD 52.4 Billion
• CAGR (2025-2034): 10.7 %
• Key Segments: Indication, Formulation, Distribution Channel, and Region
• Leading Companies: Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Boehringer Ingelheim, AstraZeneca plc, Sanofi S.A., and Intarcia Therapeutics Inc.

Market Story
Liraglutide (Victoza®, Saxenda®) and Semaglutide (Ozempic®, Rybelsus®, Wegovy®) have become cornerstone therapies for type 2 diabetes and obesity management. Their ability to mimic endogenous GLP-1 hormones enables appetite suppression, delayed gastric emptying, and improved insulin secretion - offering dual metabolic and cardiovascular benefits.

Following the global surge in obesity and lifestyle-related metabolic diseases, clinicians are increasingly prescribing GLP-1 analogs not only for diabetic patients but also for weight-management populations. The development of once-weekly injectables and oral GLP-1 formulations, along with ongoing research into combination GLP-1/GIP and GLP-1/glucagon co-agonists, is expected to maintain robust market expansion.

Market Segmentation
By Indication: Type 2 Diabetes Mellitus, Obesity and Overweight Management, Cardiovascular Risk Reduction, Others

By Formulation: Injectable Liraglutide, Injectable Semaglutide, Oral Semaglutide

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/48108/liraglutide-and-semaglutide-market

Recent Developments
• Novo Nordisk A/S expanded global production capacity for Wegovy® to meet unprecedented obesity-drug demand.
• Eli Lilly advanced its next-generation dual GLP-1/GIP agonist Tirzepatide while exploring co-formulations with Semaglutide.
• Pfizer entered late-stage trials for oral GLP-1 candidates designed to compete directly with Rybelsus®.
• AstraZeneca initiated research partnerships for long-acting GLP-1 implants improving adherence.
• Boehringer Ingelheim invested in peptide-stability and depot-delivery platforms to reduce dosing frequency.

Expert Insight
"GLP-1 therapies have transformed metabolic medicine, merging diabetes care with effective weight reduction. As oral and multi-agonist innovations accelerate, this market will continue to redefine chronic-disease management,"
- Lead Analyst, Exactitude Consultancy

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=48108

Market Drivers
• Global Obesity Epidemic: Over 1 billion adults worldwide are classified as obese, driving long-term therapy adoption.
• Expanded Indications: Regulatory approvals for cardiovascular benefit and weight-loss management.
• Innovation in Drug Delivery: Shift from daily injections to oral and once-weekly formulations.
• Government and Payer Support: Coverage expansion for anti-obesity prescriptions in developed markets.

Forecast & Regional Insights
North America leads with over 50 % market share (2024) thanks to high disease prevalence and favorable reimbursement. Europe follows with rising adoption in weight-management clinics and preventive-care initiatives. Asia Pacific is anticipated to record the fastest CAGR of 12.4 %, driven by increasing diabetes diagnoses and greater access to biologic injectables in China, Japan, and India.

Conclusion
The Liraglutide and Semaglutide market underscores a historic shift in metabolic-disease care - from glycemic control to comprehensive weight and cardiovascular management. With biotech advancements and expanding patient awareness, GLP-1 therapies are set to dominate the next decade of chronic-disease pharmacotherapy.

This report is also available in the following languages : Japanese (リラグルチドとセマグルチド), Korean (리라글루티드와 세마글루티드), Chinese (利拉鲁肽和索马鲁肽), French (Liraglutide et sémaglutide), German (Liraglutid und Semaglutid), and Italian (Liraglutide e Semaglutide), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/48108/liraglutide-and-semaglutide-market#request-a-sample

Related Reports

GLP-1 Market
https://exactitudeconsultancy.com/reports/72406/glp-1-market

GLP-1 Diabetes Treatment Drugs Market
https://exactitudeconsultancy.com/reports/74996/glp-1-diabetes-treatment-drugs-market

Oligonucleotide Synthesis Market
https://exactitudeconsultancy.com/reports/31156/oligonucleotide-synthesis-market

Wet Age-Related Macular Degeneration Market
https://exactitudeconsultancy.com/reports/34683/wet-age-related-macular-degeneration-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.